Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis

Alexander J. Neuwelt, Tam M. Nguyen, Rongwei Fu, Joseph Bubalo, Rose M.arie Tyson, Cynthia Lacy, Seymur Gahramanov, Morad Nasseri, Penelope D. Barnes, Edward A. Neuwelt

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

AIMS: Prophylaxis against Pneumocystis jiroveci pneumonia (PJP) is currently recommended for patients receiving chemoradiation with temozolomide for newly diagnosed glioblastoma multiforme. At our institution, PJP prophylaxis during temozolomide treatment has not been routinely given because of the paucity of supporting data. We investigated the rate of PJP infections in our patients.

PATIENTS & METHODS: We conducted a retrospective chart review of 240 brain tumor patients treated between 1999 and 2012 with temozolomide and no PJP prophylaxis, 127 of which received concurrent chemoradiation.

RESULTS: One in 240 patients (0.4%; 95% CI: 0.01-2.00; median total dose: 7375 mg/m(2); interquartile range: 1300) were diagnosed with PJP.

CONCLUSION: There was a <1% rate of PJP for brain tumor patients treated with temozolomide until progression without PJP prophylaxis.

Original languageEnglish (US)
Pages (from-to)267-273
Number of pages7
JournalCNS oncology
Volume3
Issue number4
DOIs
StatePublished - Jul 1 2014

    Fingerprint

Keywords

  • Pneumocystis jirovecii
  • brain radiation
  • glioblastoma
  • temozolomide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neuwelt, A. J., Nguyen, T. M., Fu, R., Bubalo, J., Tyson, R. M. A., Lacy, C., Gahramanov, S., Nasseri, M., Barnes, P. D., & Neuwelt, E. A. (2014). Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis. CNS oncology, 3(4), 267-273. https://doi.org/10.2217/cns.14.24